Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Turning Point

Merger Arbitrage Mondays – Bristol Myers (BMY) Acquires Third Point Therapeutics (TPTX)

Another week and another deal with big pharma buying out a development stage oncology company. Given the real synergies to be had through young companies partnering with big pharma to leverage their manufacturing expertise and distribution networks, regulators have allowed most of them to go through and they tend to…

Biotech buyout: San Diego's Turning Point Therapeutics sells to Bristol Myers Squibb for $4.1 billion

Bristol Myers Squibb has inked a deal to buy San Diego's Turning Point Therapeutics for $4.1 billion in cash, strengthening the pharmaceutical giant's presence in precision cancer treatments.

Tribune News Service

Bristol Myers Snaps Up Turning Point For $4.1 Billion In Cash — Is The Biotech Bear Dead?

Bristol Myers Snaps Up Turning Point For $4.1 Billion In Cash — Is The Biotech Bear Dead?

Turning Point Therapeutics snagged a $4.1 billion offer from Bristol Myers Squibb on Friday, and TPTX stock more than doubled.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Expert Ratings for Turning Point

Over the past 3 months, 4 analysts have published their opinion on Turning Point (NASDAQ:TPTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2022

Focus V Nabs Turning Point Canada As Exclusive Distributor, Cannabis Heating Devices Will Benefit

Focus V line of product offerings is now available in Canada, exclusively distributed by Turning Point Brands (NYSE: TPB).

12 Health Care Stocks Moving In Wednesday's Intraday Session

inkl

Read news from The Economist, FT, and more,
with one subscription

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal

'Caring' man, 21, fell from viaduct despite desperate attempts of police officers, inquest hears

'Caring' man, 21, fell from viaduct despite desperate attempts of police officers, inquest hears

'I would like to commend PC Oliver for his actions that day. It’s clear that he’s a very caring officer who tried his best to help Elliot'

Manchester Evening News

Charlie Kirk’s plans for ‘America First’ school in doubt as contractor pulls out

Charlie Kirk’s plans for ‘America First’ school in doubt as contractor pulls out

Turning Point USA online learning academy claimed students were being taught a ‘false narrative about America’

The Independent UK

David Lat on the Crystal Clanton Matter

As usual, Lat puts it very well in his "Original Jurisdiction" Substack newsletter (I've paid for a subscription, and highly recommend it): Last fall, [Chief Judge Pryor] was widely criticized for hiring an allegedly racist law clerk—specifically, Crystal Clanton, now a 3L at George Mason aka Scalia Law. According to…

People

Clarence Thomas

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Turning Point USA

B of A Securities

Ollie Bargain Outlet

Bristol Myers Squibb

Hewlett Packard

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

302,882 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play